皮肤分枝杆菌感染再思考：从流行病学到防治策略

doi:10.35541/cjd.20240467

中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (11): 1011-1015.doi: 10.35541/cjd.20240467

皮肤分枝杆菌感染再思考：从流行病学到防治策略

王洪生甘甜

中国医学科学院北京协和医学院皮肤病医院分枝杆菌实验室，南京 210042

收稿日期:2024-09-03 修回日期:2024-10-12 发布日期:2024-10-31
通讯作者: 王洪生 E-mail:whs33@vip.sina.com

Rethinking cutaneous mycobacterial infections: from epidemiology to prevention and treatment strategies

Wang Hongsheng, Gan Tian

Laboratory of Mycobacteriology, Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China

Received:2024-09-03 Revised:2024-10-12 Published:2024-10-31
Contact: Wang Hongsheng E-mail:whs33@vip.sina.com

摘要/Abstract

摘要： 【摘要】皮肤分枝杆菌感染是一种由分枝杆菌属细菌引起的慢性感染，通常影响皮肤和软组织。近年来，随着全球人口流动的增加和环境变化，皮肤分枝杆菌感染的流行病学特征发生了变化。本文旨在重新审视皮肤分枝杆菌感染的流行病学、治疗策略以及预防措施,以期提升皮肤分枝杆菌感染的诊疗水平，促进皮肤分枝杆菌感染的防控。

关键词: 分枝杆菌感染, 皮肤, 流行病学, 诊断, 防治策略

Abstract: 【Abstract】 Cutaneous mycobacterial infections are a kind of chronic infection caused by the genus Mycobacterium that usually affects the skin and soft tissues. The epidemiological features of cutaneous mycobacterial infections have undergone changes in recent years with the increase in global population mobility and environmental changes. This review aims to re-examine the epidemiology of, treatment strategies for, and preventive measures for cutaneous mycobacterial infections so as to enhance their diagnosis and treatment and to promote their prevention and control.

Key words: Mycobacterium infections, Skin, Epidemiology, Diagnosis, Prevention and treatment measures

王洪生甘甜. 皮肤分枝杆菌感染再思考：从流行病学到防治策略[J]. 中华皮肤科杂志, 2024,57(11):1011-1015. doi:10.35541/cjd.20240467

Wang Hongsheng, Gan Tian. Rethinking cutaneous mycobacterial infections: from epidemiology to prevention and treatment strategies[J]. Chinese Journal of Dermatology, 2024, 57(11): 1011-1015.doi:10.35541/cjd.20240467

参考文献 58

［1］	WHO. Global tuberculosis report 2023［EB/OL］. （2023⁃11⁃07）［2024⁃08⁃18］. https://www.who.int/publications/i/item/9789240083851.
［2］	WHO. Global tuberculosis report 2019［EB/OL］. （2019⁃10⁃15）［2024⁃08⁃18］. https://www.who.int/publications/i/item/9789241565714.
［3］	Li T, Yan X, Du X, et al. Extrapulmonary tuberculosis in China: a national survey［J］. Int J Infect Dis, 2023,128:69⁃77. doi: 10.1016/j.ijid.2022.12.005.
［4］	Mwiru RS, Nagu TJ, Kaduri P, et al. Prevalence and factors associated with alcohol drinking among HIV and tuberculosis co⁃infected patients in Dar es Salaam, Tanzania［J］. AIDS Care, 2018,30（2）:173⁃177. doi: 10.1080/09540121.2017.1344183.
［5］	Ankrah AO, Glaudemans A, Maes A, et al. Tuberculosis［J］. Semin Nucl Med, 2018,48（2）:108⁃130. doi: 10.1053/j.semnuclmed.2017.10.005.
［6］	Chen Q, Chen W, Hao F. Cutaneous tuberculosis: a great imitator［J］. Clin Dermatol, 2019,37（3）:192⁃199. doi: 10.1016/j.clindermatol.2019.01.008.
［7］	Maymone M, Laughter M, Venkatesh S, et al. Leprosy: clinical aspects and diagnostic techniques［J］. J Am Acad Dermatol, 2020,83（1）:1⁃14. doi: 10.1016/j.jaad.2019.12.080.
［8］	World Health Organization. World Health Organization. Global leprosy （hansen disease） update, 2019: time to step⁃up prevention initiatives［J］. Wkly Epidemiol Rec, 2020,95（36）:417⁃440.
［9］	World Health Organization. Global leprosy （hansen disease） update, 2022: new paradigm⁃control to elimination［J］. Wkly Epidemiol Rec, 2023, 98（37）: 409⁃430.
［10］	Shi Y, Sun PW, Wang L, et al. Epidemiology of leprosy in China, 2021: an update: ［J］. Int J Dermatol Venereol, 2024,7（1）:35⁃39. doi: 10.1097/JD9.0000000000000344.
［11］	Matsumoto Y, Kinjo T, Motooka D, et al. Comprehensive subspecies identification of 175 nontuberculous mycobacteria species based on 7547 genomic profiles［J］. Emerg Microbes Infect, 2019,8（1）:1043⁃1053. doi: 10.1080/22221751.2019.163 7702.
［12］	Fujishima C, Tahara J, Munemoto S, et al. Cutaneous nontuberculous mycobacterial infections in Japan: review of the Japanese literature［J］. J Dermatol, 2022,49（11）:1075⁃1084. doi: 10.1111/1346⁃8138.16531.
［13］	Sander MA, Isaac⁃Renton JL, Tyrrell GJ. Cutaneous nontuberculous mycobacterial infections in Alberta, Canada: an epidemiologic study and review［J］. J Cutan Med Surg, 2018,22（5）:479⁃483. doi: 10.1177/1203475418776945.
［14］	Mei Y, Zhang W, Shi Y, et al. Cutaneous tuberculosis and nontuberculous mycobacterial infections at a national specialized hospital in China［J］. Acta Derm Venereol, 2019,99（11）:997⁃1003. doi: 10.2340/00015555⁃3283.
［15］	Johansen MD, Herrmann JL, Kremer L. Non⁃tuberculous mycobacteria and the rise of Mycobacterium abscessus［J］. Nat Rev Microbiol, 2020,18（7）:392⁃407. doi: 10.1038/s41579⁃020⁃0331⁃1.
［16］	Wentworth AB, Drage LA, Wengenack NL, et al. Increased incidence of cutaneous nontuberculous mycobacterial infection, 1980 to 2009: a population⁃based study［J］. Mayo Clin Proc, 2013,88（1）:38⁃45. doi: 10.1016/j.mayocp.2012.06.029.
［17］	Chirasuthat P, Triyangkulsri K, Rutnin S, et al. Cutaneous nontuberculous mycobacterial infection in Thailand: a 7⁃year retrospective review［J］. Medicine （Baltimore）, 2020,99（10）:e19355. doi: 10.1097/MD.0000000000019355.
［18］	Franco⁃Paredes C, Marcos LA, Henao⁃Martínez AF, et al. Cutaneous mycobacterial infections［J］. Clin Microbiol Rev, 2018,32（1）:e00069⁃00018. doi: 10.1128/CMR.00069⁃18.
［19］	Henkle E, Winthrop KL. Nontuberculous mycobacteria infections in immunosuppressed hosts［J］. Clin Chest Med, 2015,36（1）:91⁃99. doi: 10.1016/j.ccm.2014.11.002.
［20］	Bohlen J, Zhou Q, Philippot Q, et al. Human MCTS1⁃dependent translation of JAK2 is essential for IFN⁃γ immunity to mycobacteria［J］. Cell, 2023,186（23）:5114⁃5134.e27. doi: 10.1016/j.cell.2023.09.024.
［21］	Qiu Y, Fang G, Ye F, et al. Pathogen spectrum and immunotherapy in patients with anti⁃IFN⁃γ autoantibodies: a multicenter retrospective study and systematic review［J］. Front Immunol, 2022,13:1051673. doi: 10.3389/fimmu.2022.1051673.
［22］	Mufti AH, Toye BW, Mckendry RR, et al. Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use［J］. Diagn Microbiol Infect Dis, 2005,53（3）:233⁃238. doi: 10.1016/j.diagmicrobio.2005.06.006.
［23］	Sauer ME, Salomão H, Ramos GB, et al. Genetics of leprosy: expected⁃and unexpected⁃developments and perspectives［J］. Clin Dermatol, 2016,34（1）:96⁃104. doi: 10.1016/j.clindermatol. 2015.10.005.
［24］	Muniyandi M, Singh M, Singh M, et al. Cost⁃effectiveness of incorporating Mycobacterium indicus pranii vaccine to multidrug therapy in newly diagnosed leprosy cases for better treatment outcomes & immunoprophylaxis in contacts as leprosy control measures for National Leprosy Eradication Programme in India［J］. Indian J Med Res, 2021,154（1）:121⁃131. doi: 10. 4103/ijmr.IJMR_661_20.
［25］	van Ingen J, Kuijper EJ. Drug susceptibility testing of nontuberculous mycobacteria［J］. Future Microbiol, 2014,9（9）:1095⁃1110. doi: 10.2217/fmb.14.60.
［26］	Gardini G, Gregori N, Matteelli A, et al. Mycobacterial skin infection［J］. Curr Opin Infect Dis, 2022,35（2）:79⁃87. doi: 10. 1097/QCO.0000000000000820.
［27］	Wallace JR, Mangas KM, Porter JL, et al. Mycobacterium ulcerans low infectious dose and mechanical transmission support insect bites and puncturing injuries in the spread of Buruli ulcer［J］. PLoS Negl Trop Dis, 2017,11（4）:e0005553. doi: 10.1371/journal.pntd.0005553.
［28］	Wang SH, Pancholi P. Mycobacterial skin and soft tissue infection［J］. Curr Infect Dis Rep, 2014,16（11）:438. doi: 10. 1007/s11908⁃014⁃0438⁃5.
［29］	Jiang H, Jin Y, Vissa V, et al. Molecular characteristics of Mycobacterium tuberculosis strains isolated from cutaneous tuberculosis patients in China［J］. Acta Derm Venereol, 2017,97（4）:472⁃477. doi: 10.2340/00015555⁃2577.
［30］	Mei YM, Zhang WY, Sun JY, et al. Genomic characteristics of Mycobacterium tuberculosis isolates of cutaneous tuberculosis［J］. Front Microbiol, 2023,14:1165916. doi: 10.3389/fmicb.2023. 1165916.
［31］	Allué⁃Guardia A, García JI, Torrelles JB. Evolution of drug⁃resistant Mycobacterium tuberculosis strains and their adaptation to the human lung environment［J］. Front Microbiol, 2021,12:612675. doi: 10.3389/fmicb.2021.612675.
［32］	Li X, Li G, Yang J, et al. Drug resistance （Dapsone, Rifampicin, Ofloxacin） and resistance⁃related gene mutation features in leprosy patients: a systematic review and meta⁃analysis［J］. Int J Mol Sci, 2022,23（20）:12443. doi: 10.3390/ijms232012443.
［33］	Rosa PS, D'Espindula H, Melo A, et al. Emergence and transmission of drug⁃/multidrug⁃resistant Mycobacterium leprae in a former leprosy colony in the Brazilian Amazon［J］. Clin Infect Dis, 2020,70（10）:2054⁃2061. doi: 10.1093/cid/ciz570.
［34］	Johansen MD, Herrmann JL, Kremer L. Non⁃tuberculous mycobacteria and the rise of Mycobacterium abscessus［J］. Nat Rev Microbiol, 2020,18（7）:392⁃407. doi: 10.1038/s41579⁃020⁃0331⁃1.
［35］	van Ingen J, Boeree MJ, van Soolingen D, et al. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria［J］. Drug Resist Updat, 2012,15（3）:149⁃161. doi: 10.1016/j.drup.2012.04.001.
［36］	Liu CF, Song YM, He WC, et al. Nontuberculous mycobacteria in China: incidence and antimicrobial resistance spectrum from a nationwide survey［J］. Infect Dis Poverty, 2021,10（1）:59. doi: 10.1186/s40249⁃021⁃00844⁃1.
［37］	Lin WH, Yao C, Mei L, et al. Screening, epidemic trends and drug sensitivity analysis of nontuberculous mycobacteria in a local area of China［J］. Am J Transl Res, 2024,16（7）:3298⁃3305. doi: 10.62347/MAJY5046.
［38］	Hunkins JJ, de⁃Moura VC, Eddy JJ, et al. In vitro susceptibility patterns for rapidly growing nontuberculous mycobacteria in the United States［J］. Diagn Microbiol Infect Dis, 2023,105（3）:115882. doi: 10.1016/j.diagmicrobio.2022.115882.
［39］	Calado Nogueira de Moura V, Nguyen MH, Hunkins JJ, et al. In vitro susceptibility patterns for slowly growing non⁃tuberculous mycobacteria in the USA from 2018 to 2022［J］. J Antimicrob Chemother, 2023,78（12）:2849⁃2858. doi: 10.1093/jac/dkad317.
［40］	Roy A, Eisenhut M, Harris RJ, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta⁃analysis［J］. BMJ, 2014,349:g4643. doi: 10.1136/bmj.g4643.
［41］	Zimmermann P, Finn A, Curtis N. Does BCG vaccination protect against nontuberculous mycobacterial infection? A systematic review and meta⁃analysis［J］. J Infect Dis, 2018,218（5）:679⁃687. doi: 10.1093/infdis/jiy207.
［42］	Lange C, Aaby P, Behr MA, et al. 100 years of Mycobacterium bovis bacille Calmette⁃Guérin［J］. Lancet Infect Dis, 2022,22（1）:e2⁃e12. doi: 10.1016/S1473⁃3099（21）00403⁃5.
［43］	World Health Organization. Leprosy/hansen disease: contact tracing and post⁃exposure prophylaxis: technical guidance［M/OL］. （2020⁃11⁃15）［2024⁃08⁃18］. https://www.who.int/publications/i/item/9789290228073.
［44］	Wang L, Wang H, Yan L, et al. Single⁃dose rifapentine in household contacts of patients with leprosy［J］. N Engl J Med, 2023,388（20）:1843⁃1852. doi: 10.1056/NEJMoa2205487.
［45］	中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟，中国麻风防治协会皮肤性病检验与诊断分会. 中国皮肤结核临床诊疗专家共识（2024版）［J］. 中华皮肤科杂志, 2024,57（5）:426⁃434. doi: 10.35541/cjd.20230354.
［46］	Kromer C, Fabri M, Schlapbach C, et al. Diagnosis of mycobacterial skin infections［J］. J Dtsch Dermatol Ges, 2019,17（9）:889⁃893. doi: 10.1111/ddg.13925.
［47］	中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟, 中国麻风防治协会皮肤性病检验与诊断分会. 中国皮肤非结核分枝杆菌病诊治专家共识（2024版）［J］. 中华皮肤科杂志, 2024,57（2）:109⁃118. doi: 10.35541/cjd.20230371.
［48］	黄海荣. 非结核分枝杆菌相关实验室检查及其结果解读［J］. 中华结核和呼吸杂志, 2020,43（11）:910⁃913. doi: 10.3760/cma.j.cn112147⁃20200316⁃00346.
［49］	Jiang H, Shi Y, Chokkakula S, et al. Utility of multi⁃target Nested PCR and ELISPOT assays for the detection of paucibacillary leprosy: a possible conclusion of clinical laboratory misdiagnosis［J］. Front Cell Infect Microbiol, 2022,12:814413. doi: 10.3389/fcimb.2022.814413.
［50］	Huang C, Huang Y, Wang Z, et al. Multiplex PCR⁃based next generation sequencing as a novel, targeted and accurate molecular approach for periprosthetic joint infection diagnosis［J］. Front Microbiol, 2023,14:1181348. doi: 10.3389/fmicb.2023. 1181348.
［51］	Tsuchida S, Umemura H, Nakayama T. Current status of matrix⁃assisted laser desorption/ionization⁃time⁃of⁃flight mass spectrometry （MALDI⁃TOF MS） in clinical diagnostic microbiology［J］. Molecules, 2020,25（20）:4775. doi: 10.3390/molecules25204775.
［52］	Wu X, Tan G, Yang J, et al. Prediction of Mycobacterium tuberculosis drug resistance by nucleotide MALDI⁃TOF⁃MS［J］. Int J Infect Dis, 2022,121:47⁃54. doi: 10.1016/j.ijid.2022.04.061.
［53］	Alcaide F, Amlerová J, Bou G, et al. How to: identify non⁃tuberculous Mycobacterium species using MALDI⁃TOF mass spectrometry［J］. Clin Microbiol Infect, 2018,24（6）:599⁃603. doi: 10.1016/j.cmi.2017.11.012.
［54］	Barker C, Alshaikh H, Elston D. Dermatology practice updates in mycobacterial disease［J］. Int J Dermatol, 2024,63（6）:714⁃725. doi: 10.1111/ijd.16969.
［55］	Alemu Belachew W, Naafs B. Position statement: LEPROSY: diagnosis, treatment and follow⁃up［J］. J Eur Acad Dermatol Venereol, 2019,33（7）:1205⁃1213. doi: 10.1111/jdv.15569.
［56］	Lamb RC, Dawn G. Cutaneous non⁃tuberculous mycobacterial infections［J］. Int J Dermatol, 2014,53（10）:1197⁃1204. doi: 10.1111/ijd.12528.
［57］	Zhang X, Liu W, Liu W, et al. Cutaneous infections caused by rapidly growing mycobacteria: case reports and review of clinical and laboratory aspects［J］. Acta Derm Venereol, 2015,95（8）:985⁃989. doi: 10.2340/00015555⁃2105.
［58］	Gao X, Ding C, Xie D, et al. Contezolid⁃containing regimen successfully treated multiple drug resistance Mycobacterium Abscessus complex infection of skin: a case report and literature review［J］. Infect Drug Resist, 2024,17:1243⁃1249. doi: 10.2147/IDR.S453541.

[1]	邹先彪陈锦纯曾悦郝轶. [开放获取] 超声检查在皮肤科的应用前景[J]. 中华皮肤科杂志, 2024, 57(9): 785-790.
[2]	蒋俊青齐潇丽李群燕顾安康张理涛. 儿童良性淋巴浆细胞斑块1例[J]. 中华皮肤科杂志, 2024, 57(9): 821-824.
[3]	曾悦邵惠红林诗雯温柔邹先彪. 可穿戴远程会诊设备在常见皮肤病诊断中的应用[J]. 中华皮肤科杂志, 2024, 57(9): 797-800.
[4]	何兰马玲姜倩陈柳青陈红英. 非生殖器部位硬化性苔藓57例皮肤镜与反射式共聚焦显微镜影像特征分析[J]. 中华皮肤科杂志, 2024, 57(9): 791-796.
[5]	乔嘉熙夏萍陈柳青. 司库奇尤单抗治疗前后银屑病局部皮损皮肤镜和反射式共聚焦显微镜特征分析[J]. 中华皮肤科杂志, 2024, 57(9): 825-829.
[6]	中国中西医结合学会皮肤性病专业委员会中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. 反射式共聚焦显微镜在常见黑素细胞性皮肤肿瘤中的应用专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(9): 775-784.
[7]	张嘉琪吴凡韩雨晴刘琦盘瑶. 多光子显微镜在皮肤科中的应用[J]. 中华皮肤科杂志, 2024, 57(9): 857-862.
[8]	黄淑黛王大光. 甲与甲病的皮肤影像学进展[J]. 中华皮肤科杂志, 2024, 57(9): 866-869.
[9]	叶嘉琪柴维敏郑捷曹华. 从皮损类型、血清标志物和影像学特征评估皮肌炎合并肺间质病变 [J]. 中华皮肤科杂志, 2024, 57(9): 863-866.
[10]	郝峰刘国艳. [开放获取] 光学相干断层扫描技术在皮肤科的应用进展[J]. 中华皮肤科杂志, 2024, 57(9): 853-857.
[11]	华优任海燕宋秀祖. 持久性色素异常性红斑5例皮肤镜和反射式共聚焦显微镜特征分析[J]. 中华皮肤科杂志, 2024, 57(9): 830-832.
[12]	王瑞霞曲岩磊艾文锦闫琳曲才杰史同新. 非大疱性嗜中性红斑狼疮1例[J]. 中华皮肤科杂志, 2024, 57(9): 832-834.
[13]	左墨刘国艳. 皮肤影像技术辅助确定基底细胞癌手术切缘的应用进展[J]. 中华皮肤科杂志, 2024, 57(9): 850-852.
[14]	张蓉菊朱月倩周乃慧钱齐宏. 瘢痕疙瘩的影像学研究进展[J]. 中华皮肤科杂志, 2024, 57(9): 846-849.
[15]	王冠钰孙佳辰李婷婷王艺萌张春雷. 西达本胺联合姜黄素对皮肤T细胞淋巴瘤的作用及机制研究[J]. 中华皮肤科杂志, 2024, 57(8): 728-738.

皮肤分枝杆菌感染再思考：从流行病学到防治策略

Rethinking cutaneous mycobacterial infections: from epidemiology to prevention and treatment strategies

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 58

相关文章 15

Metrics

本文评价

推荐阅读 10